Bairui granules versus Reyanning granules in adults with acute bronchitis: a multicenter, randomized, double-blind, double-dummy, comparative trial
Frontiers in Pharmacology · 16.07.2026 · 17
DOI: 10.3389/fphar.2026.1860478 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.07.2026. Verfasst von Youqiang Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bairui granules, a monotherapy derived from Thesium chinense Turcz., are widely used in respiratory tract infections, yet high-quality clinical evidence for their effectiveness in acute bronchitis is lacking.
Purpose
To evaluate the effectiveness and safety of Bairui granules in patients with acute bronchitis (Wind-heat invading lung syndrome). Study Design The study (ChiCTR2200063906) was a multicenter, randomized, double-blind, double-dummy, comparative trial.
Methods
Eligible participants from seven hospitals were randomized 2:1 to receive either Bairui granules plus placebo matching Reyanning Granules (experimental group) or Reyanning granules plus placebo matching Bairui Granules (control group) orally for 7 days. The primary endpoint was cough resolution rate after treatment. Secondary endpoints included time to cough and sputum resolution, area under the curve (AUC) for cough and sputum severity, bronchitis severity score (BSS), and traditional Chinese medicine (TCM) symptom scores.
Results
Of 162 randomized patients, 161 completed the trial (107 experimental, 54 control). The cough resolution rate was higher in the experimental group than in the control group (72.22% vs. 35.19%; P < 0.0001). The time to cough resolution was 144 h (120,156) versus 168 h (138, 168) ( P = 0.001). AUC for cough severity was 184.3 versus 214.3 score·h ( P = 0.023). The BSS improvement at Day 9 was −4.82 (3.54) versus −4.30 (0.71) ( P = 0.068). The daytime cough TCM score improved by −6 (−6, −6) versus −6 (−6, −3) ( P = 0.003), and the sputum score improved by −3 (−6, −3) versus −3 (−3, −3) ( P = 0.031). Greater improvements were also observed in aversion to wind symptoms (Day 4) and sore throat symptoms (Day 9) in the experimental group. Adverse-event rates were similar between the two groups. All events were mild to moderate in severity and reversible.
Conclusion
Bairui granules resulted in a higher cough-resolution rate and faster cough resolution than Reyanning granules in adults with acute bronchitis. The treatment was well tolerated. Clinical Trial Registration https://www.chictr.org.cn/hvshowproject.html?id=193073&v=1.0 , identifier ChiCTR2200063906.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Respiratory Department, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China.
- OISE Department of Applied Psychology & Human Development, University of Toronto, Toronto, ON, Canada.
Zitieren
APA
Wu, Y., Shen, G., Ji, S., Liu, G., Nie, W., Xue, B., Zuo, C., Du, Y., Qi, J., Wang, M., Ban, C., & Cheng, M. (2026). Bairui granules versus Reyanning granules in adults with acute bronchitis: a multicenter, randomized, double-blind, double-dummy, comparative trial. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1860478
Vancouver
Wu Y, Shen G, Ji S, Liu G, Nie W, Xue B, et al. Bairui granules versus Reyanning granules in adults with acute bronchitis: a multicenter, randomized, double-blind, double-dummy, comparative trial. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1860478
BibTeX
@article{Wu2026,
author = {Wu, Youqiang and Shen, Guantong and Ji, Shuyang and Liu, Guoxing and Nie, Weicheng and Xue, Bei and Zuo, Chen and Du, Yingjie and Qi, Jingyi and Wang, Mingzhe and Ban, Chengjun and Cheng, Miao},
title = {Bairui granules versus Reyanning granules in adults with acute bronchitis: a multicenter, randomized, double-blind, double-dummy, comparative trial},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1860478}
}
EUVIMED